
AlloNK Plus Rituximab Induces Durable Responses in R/R B-Cell NHL
The combination of AlloNK (AB-101) plus rituximab (Rituxan) produced high complete response (CR) rates and prolonged responses beyond 12 months in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-cell NHL), according to updated data …